Northwest Biotherapeutics, Inc. Common stock

NWBO

NWBO Hedge Fund Activity: Q1 2026 in Review

8 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q1 2026, worth a combined $83.3K — up 91% from $43.7K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new NWBO positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Kelleher Financial Advisors, opening a new position worth an estimated $41.3K. The largest seller was Advisors Management Group, exiting entirely with an estimated $2K sold.

• 8 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q1 2026, up from 7 in Q4 2025.
• Funds reported $83.3K of Northwest Biotherapeutics, Inc. Common stock stock for Q1 2026, up 91% quarter-over-quarter.
• 2 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q1 2026 and 1 closed out, a net change of +1 holder.
• The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q1 2026 was Kelleher Financial Advisors, an estimated $41.3K added.
• The largest Northwest Biotherapeutics, Inc. Common stock seller in Q1 2026 was Advisors Management Group, an estimated $2K sold.

Based on aggregated 13F filings for Q1 2026.